Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Investor Presentation (January 2015)

30 slides from Enumeral Biomedical's investor presentation, Jan 9, 2015

  1. Slide 1: Enumeral Overview January 2015

    Slide 1: Enumeral Overview January 2015

    THE POWER of HUMAN™ Enumeral Overview January 2015 Arthur H. Tinkelenberg , Ph.D. President and CEO

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements OTC QB: ENUM THIS PRESENTATION CONTAINS FORWARD - LOOKING STATEMENTS THAT ARE BASED ON THE COMPANY’S CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND PROJECTIONS ABOUT THE COMPANY AND THE PHARMACEUTICAL INDUSTRY. THE COMPANY MAKES NO REPRESENTATIONS ABOUT THE ACCURACY OF S

  3. Slide 3: Enumeral's Mission

    Slide 3: Enumeral's Mission

    Enumeral’s Mission Discover and Develop Best - In - Class Antibody Immunotherapies Using Our Proprietary Platform that Uniquely Leverages Human Cell Biology 3

  4. Slide 4: Human is Better

    Slide 4: Human is Better

    Human is Better Research models do not predict human response to immunotherapies 4 Conventional Approach Enumeral’s Differentiated Approach Enumeral’s technology enables selection of best - in - class candidates using human cells from patients

  5. Slide 5: Immunotherapy market opportunity

    Slide 5: Immunotherapy market opportunity

    Immunotherapy market opportunity • Immunotherapy predicted to generate sales of up to $35 billion per year over next 10 years and treat up to 60% of all cancers* • Yervoy proves clinical and commercial success is tenable - launched in 2011 , >$ 1B in revenue year ended June 30th, 2014** • Strong int

  6. Slide 6: Why is it Difficult to Develop Novel Immunotherapies?

    Slide 6: Why is it Difficult to Develop Novel Immunotherapies?

    Why is it Difficult to Develop Novel Immunotherapies? ‘Mechanisms of action’ difficult to measure → Immunotherapy changes ‘behavior’ of immune system Disease ‘models’ not predictive → Research models are not predictive of human disease 6 Rare human cells that underlie disease processes → Difficult t

  7. Slide 7: Enumeral opportunity

    Slide 7: Enumeral opportunity

    Enumeral opportunity • Antibody immunotherapies : proven immunotherapy class; product category understood; high demand • Ongoing programs targeting checkpoint proteins: PD - 1, OX40, Lag - 3, others; candidates and indications selected using Enumeral’s ‘Human Approach’ for cancer and non - cancer in

  8. Slide 8: Enumeral's Differentiation

    Slide 8: Enumeral's Differentiation

    Enumeral’s Differentiation • Many technologies focused on drug candidate discovery • Few platforms that can also address will they work , and if so, in whom … • Proprietary platform developed at Harvard and MIT – Enables rapid discovery of antibody candidates , faster, cheaper, and with substantiall

  9. Slide 9: Smaller is Better

    Slide 9: Smaller is Better

    Smaller is Better Measuring rare cells in human samples is like finding a needle in a haystack Enumeral’s technology shrinks the haystack closer to the size of the needle 9 3.0 mm Conventional Wells Enumeral’s Proprietary Nanowells (160,000x smaller volume) 0.05 mm Detection Minimum Signal Signal De

  10. Slide 10: Enumeral's Platform

    Slide 10: Enumeral's Platform

    Enumeral’s Platform 10 84,672 microwells Proprietary high - density bio - chip and one - day process measures key parameters of function of individual immune cells from patient samples: Determine cell function through cell secretions Determine cell type and biological function R ecover cells of inte

  11. Slide 11: Validation – NCI Sponsored Contract

    Slide 11: Validation – NCI Sponsored Contract

    Validation – NCI Sponsored Contract 11 Enumeral’s technology enables extensive interrogation of the immune microenvironment in human biopsy samples

  12. Slide 12: Platform Enables Study of Disease in Humans at Disease Site

    Slide 12: Platform Enables Study of Disease in Humans at Disease Site

    Enumeral’s Platform Enables Study of Disease in Humans at Disease Site 12 Enumeral’s platform enables human - based development paradigm Proprietary functional immune signatures determined from both patient groups Human Population – Biopsy Tissues Enumeral Platform Patients who benefit from treatmen

  13. Slide 13: Human-based target validation and lead selection

    Slide 13: Human-based target validation and lead selection

    Enumeral’s human - based target validation and lead selection 13 [Indication 1] [Indication 2] [Indication 3] … [Indication X] Patients Biopsy Focus on validated targets of high commercial value TILs Enumerate “Tissue - infiltrating Lymphocytes” Targets Leads Expression of targets by cell type: PD -

  14. Slide 14: Faster is Better

    Slide 14: Faster is Better

    Faster is Better 14 Enumeral believes its technology platform is faster where time to market can mean the difference of billions of dollars Target to Lead Candidate Enumeral - Estimated Development Timeline Target to Lead Candidate Traditional Pharma/Biotech 1 1 Paul et al, "How to improve R&D produ

  15. Slide 15: Enumeral Antibody Discovery Timeline

    Slide 15: Enumeral Antibody Discovery Timeline

    Enumeral Antibody Discovery Timeline Freeman & Sharpe 2012 VH VK Sequence analysis of mAb clades: 3 days • ~10 day screening process with primary B cells • Unparalleled diversity from multiple tissue types Single cell recovery and RT - PCR: 3 - 4 days Clinically - relevant target Immunization: 60 da

  16. Slide 16: First program screening output: PD-1

    Slide 16: First program screening output: PD-1

    First program screening output: PD - 1 16 Screen 1 - 12 Heavy chain AA sequences from PD1 N= 349 sequences BMY MRK MDVN • Rapid generation of broad diversity of antibody sequences • P otential for strong intellectual property around validated clinical targets

  17. Slide 17: Faster is Better

    Slide 17: Faster is Better

    17 Faster is Better 2014 2015 2016 2017 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 IND Filing IND Enabling Studies and CMC Preclinical Efficacy Phase I PD - 1: Phase I Screening IND Enabling Studies and CMC Preclinical Efficacy IND Filing Phase I Screening IND Enabling Studies and CMC Preclinic

  18. Slide 18: Program Summary

    Slide 18: Program Summary

    Program Summary • Anti - PD - 1 antibodies – First program reached initial preclinical validation of lead candidates; supports potential programs in cancer and inflammatory disease – Partnering conversations initiated • Additional programs – OX40 and Lag - 3 screening ongoing – Two new programs set

  19. Slide 19: Anti-PD-1 key questions: What is the drug mechanism?

    Slide 19: Anti-PD-1 key questions: What is the drug mechanism?

    Anti - PD - 1 key questions: “What is the drug mechanism?” 19 http://www.hematology.org/Thehematologist/Diffusion/2560.aspx • Ipilimumab , N ivolumab – Do these drug ‘deplete’ cells? Induce anergy ? Induce apoptosis? Activate T cells? What else happens? – Why are these agents active in melanoma but

  20. Slide 20: PD-1 target physiology: What is the cause of disease?

    Slide 20: PD-1 target physiology: What is the cause of disease?

    PD - 1 target physiology: “What is the cause of disease?” • Can PD - 1 be a target outside of oncology? – Are psoriasis, inflammatory bowel disease, or rheumatoid arthritis T cell diseases? – Is the (presumed) IL - 17 or IFN g coming from pathologic T cells? – Is the disease etiology universal or va

  21. Slide 21: Enumeral Business Model

    Slide 21: Enumeral Business Model

    Enumeral Business Model Multiple corporate partnering discussions ongoing • Strategic partnerships • Out - licensing and co - development • Patient response stratification • Resurrection of failed drug candidates Potential economics: License fees, research support, milestone payments and royalties 2

  22. Slide 22: Selected Immunotherapy Transactions

    Slide 22: Selected Immunotherapy Transactions

    Selected Immunotherapy Transactions Transaction* Stage Upfront Total Potential Value Milestones & Royalties Five Prime → BMS (2014) Platform Access $41,000,000 $651,000,000 Equity, R&D, Milestones, Royalties Five Prime → BMS (2014) Phase I $30,000,000 BMS pays trial costs NA Five Prime → GSK (2014)

  23. Slide 23: Enumeral and Merck Form Collaboration

    Slide 23: Enumeral and Merck Form Collaboration

    Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human - driven Immune Profiling Platform • December 18, 2014 • O ncology - focused collaboration using Enumeral's human approach to interrogate the tumor microenvironment in colorectal cancer tissues obtained directly f

  24. Slide 24: Recent Achievements

    Slide 24: Recent Achievements

    Recent Achievements • Collaboration deal signed with top immuno - oncology pharmaceutical company (Merck, December 18, 2014) • Received notice that seven patents in the Company’s intellectual property estate recently issued: three patents in the U.S. and four patents in international jurisdictions •

  25. Slide 25: Near-term Corporate Objectives

    Slide 25: Near-term Corporate Objectives

    Near - term Corporate Objectives • 2015 (1H): – Sign additional corporate partnership – Achieve key human ex vivo preclinical milestone in lead program (PD - 1) – Commence screening programs for next two targets • 2015 (2H): – Commence IND - enabling studies in first program (with a partner) – Sign

  26. Slide 26: Management Team

    Slide 26: Management Team

    Management Team • John J. Rydzewski, Executive Chairman, Co - Founder, Director Co Chair, RAND Healthcare Advisory Board, Christofferson - Robb, Kidder - Peabody, Price Waterhouse & Co., Wharton • Arthur H. Tinkelenberg , Ph.D., President & CEO, Co - Founder, Director Ascent Biomedical Ventures, Rob

  27. Slide 27: Board of Directors

    Slide 27: Board of Directors

    Board of Directors • John J. Rydzewski, Executive Chairman, Co - Founder • Arthur H. Tinkelenberg , Ph.D., President & CEO, Co - Founder • Barry Buckland , Ph.D., Co - Founder, Co - Chairman of the Scientific Advisory Board Merck’s bioprocess R&D Group; launched immunotherapy products, including GAR

  28. Slide 28: Summary: Enumeral's differentiation in immunotherapy

    Slide 28: Summary: Enumeral's differentiation in immunotherapy

    Summary: Enumeral’s differentiation in immunotherapy • Platform for developing best - in - class product candidates based on a fundamental understanding of target physiology in human cells • Unique ex vivo ‘human approach’ for antibody candidate selection using patient - derived biopsy samples • Und

  29. Slide 29: Financials & Capitalization

    Slide 29: Financials & Capitalization

    THE POWER of HUMAN ™ Category Common Shares Outstanding 51,591,710 Warrants Outstanding* 24,803,409 Options Outstanding 2,374,420 Burn Rate , Q3 ’14 ($2.1M) Total Debt $0.0M Cash and Cash Equivalents** $16.2M 29 OTC QB: ENUM Price: $1.03 Market Cap (1/7/2015) $53.14M Enumeral : uniquely positioned t

  30. Slide 30: Arthur H. Tinkelenberg, President and CEO

    Slide 30: Arthur H. Tinkelenberg, President and CEO

    THE POWER of HUMAN™ Arthur H. Tinkelenberg , Ph.D. President and CEO arthur@enumeral.com 617 - 500 - 2647

Source: SEC EDGAR · 8-K filed Jan 9, 2015

More decks from Enumeral Biomedical Holdings Inc